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Purpose
Immunotherapies aiming to interfere with the immune
checkpoint molecule PD-1 (programmed death-1) and
its ligand PD-L1 are currently being investigated in
several clinical trials to treat cancer patients. The PD-1
pathway is one of the ways cancer cells evade
immune-mediated killing. As little is known about the
expression of PD-1 and PD-L1 in cancer patients com-
pared to normal individuals, the aim of this study was
to assess PBMC subsets for expression of these
markers.
Methods
Twelve immune cell subsets were analyzed by flow-cyto-
metry in 22 cancer patients and 16 normal individuals.
The cancer patients consisted of 1 anal, 2 breast, 4
colon, 1 esophageal, 2 mesothelioma, 1 neuroendocrine,
1 non-small cell lung, 1 ovarian, 5 pancreatic, 3 renal
cell and 1 squamous cell tracheal cancer patients. The
subsets analyzed were CD4 and CD8 T cells, B cells,
conventional dendritic cells (cDC), plasmacytoid DC
(pDC), natural killer cells (NK), natural killer T cells
(NKT), myeloid derived suppressor cell (MDSC), mono-
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Figure 1 Differences in PBMC subsets and PD-1 and PD-L1 expression in cancer patients at baseline and normal individuals.
Lepone et al. Journal for ImmunoTherapy of Cancer 2014, 2(Suppl 3):P152
http://www.immunotherapyofcancer.org/content/2/S3/P152
© 2014 Lepone et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
cytic MDSC (mMDSC), granulocytic MDSC (gMDSC),
and lineage-negative MDSC (Lin-MDSC). We also ana-
lyzed surface expression of PD-1 (clone MIH4) and
PDL-1 (clone MIH1). See Figure 1.
Results
Compared to normal subjects, cancer patients had some
PBMC subsets with changes in frequency but no differ-
ences in PD-1 and PD-L1 expression (i.e., B cells,
mMDSCs, and gMDSCs). Other subsets showed changes
in PD-1 and PD-L1 expression without differences in
the frequency of the subset (i.e., CD4, Tregs, cDCs,
pDCs, NK, and MDSCs). Lin-MDSCs presented at a
higher frequency and greater PD-L1 positivity.
Conclusions
Understanding the differences of PBMC immune subsets
between normal subjects and cancer patients, and the
surface expression of PD-1 and PD-L1, can provide
insights as to which immune subsets can be targeted by
therapies aimed at interfering with the PD-1 pathway in
cancer patients.
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